Výsledky vyhledávání

Abstract OT1-17-02: A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients

Autor: Nancy Chan, Dirk Moore, Pavankumar Tandra, Jatin Rana, Coral Omene, Mridula George, Jairam Krishnamurthy, Shruti Desai, Nayana Patel, Yue Wang, Marc Bicomong, Xiao-wei Tan, Kim Hirshfield, Shridar Ganesan, Deborah Toppmeyer

Publikováno v: Cancer Research. 82:OT1-17

Background:ER positive, HER2-negative breast cancer is the most common subtype in both early and late stages. Previous studies have demonstrated a subset of patients may derive benefit from immune check point inhibitors in combination with endocrine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c1762320065daeda31f701706240c2e
https://doi.org/10.1158/1538-7445.sabcs21-ot1-17-02

Zobrazit plný text záznamu

Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer

Autor: Andrew A. Brock, Katherine Powell, Lorenzo F. Sempere, Thomas D. Schmittgen, Jatin Rana

Publikováno v: Cancer Metastasis Reviews

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer with an overall 5-year survival rate of less than 10%. The 1-year survival rate of patients with locally advanced or metastatic disease is abysmal. The aggressive natur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7578ab2d356d7ea06b5cd5c345065cf6
https://doi.org/10.1007/s10555-021-09995-x

Zobrazit plný text záznamu

Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Autor: Oana C. Danciu, Kent Hoskins, Jennifer Weiss, Cristina I. Truica, Anne Blaes, Deimante Tamkus, Jatin Rana, Tandra Pavankumar, Lauren Green, Yu Gao, Menggang Yu, Qianqian Zhao, Deborah Toppmeyer, Ruth O’Regan, Kari B. Wisinski

Publikováno v: Cancer Research. 83:P4-01

Background: Palbociclib is a CDK4/6 inhibitor used to treat metastatic hormone receptor-positive (HR+) breast cancer (MBC) in combination with endocrine therapy. Tamoxifen is an effective treatment for HR+ MBC, with different toxicity profile compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f14da66f2a8ca5393254ec304104198e
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-38

Zobrazit plný text záznamu

Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen

Autor: Ruth O'Regan, Jatin Rana, Xiuyuan Ma, Deborah Toppmeyer, Oana Cristina Danciu, Menggang Yu, Li C Liu, Yael Simons, Pavankumar Tandra, Kari B. Wisinski, Anne H. Blaes, Cristina I. Truica, Lauren Green, Gayatry Mohapatra, Louis Coleman, Yu Gao, Kent Hoskins

Publikováno v: Journal of Clinical Oncology. 39:1030-1030

1030 Background: Combining a CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) in advanced, hormone receptor (HR)-positive, HER2-negative breast cancer (BC) doubles median progression-free survival, but eventually drug resistance and disease pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::136384f254503a217ac0047a5fe33710
https://doi.org/10.1200/jco.2021.39.15_suppl.1030

Zobrazit plný text záznamu

Impact of pre-treatment lymphocyte monocyte ratio and neutrophil lymphocyte ratio on pathologic response in breast cancer patients receiving neoadjuvant chemotherapy

Autor: Shouq Kherallah, Daniel I. Isaac, Venumadhavi Gogineni, Ling Wang, Saud Alsubait, Jatin Rana, Osama Mosalem

Publikováno v: Journal of Clinical Oncology. 39:e12623-e12623

e12623 Background: Hematologic markers have been looked at as potential prognostic biomarkers in a variety of cancers. Ni and colleagues (2014) have shown that an elevated pre-treatment lymphocyte-to-monocyte ratio (LMR) was significantly associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1e9a254d9eda43c75206b93cf679794
https://doi.org/10.1200/jco.2021.39.15_suppl.e12623

Zobrazit plný text záznamu

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer

Autor: Deimante Tamkus, Deborah Toppmeyer, Menggang Yu, Kari B. Wisinski, Cristina I. Truica, Oana Cristina Danciu, Jatin Rana, Ruth O'Regan, Pavankumar Tandra, Lauren Green, Qianqian Zhao, Anne H. Blaes, Kent Hoskins

Publikováno v: Journal of Clinical Oncology. 39:1056-1056

1056 Background: Palbociclib is a CDK4/6 inhibitor used to treat metastatic hormone receptor-positive (HR+) breast cancer (MBC) in combination with endocrine therapy. Tamoxifen is an effective treatment for HR+ MBC, with different toxicity profile co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18f5e226b89e96e6727a293a94dbb5d2
https://doi.org/10.1200/jco.2021.39.15_suppl.1056

Zobrazit plný text záznamu

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Autor: Glaivy Batsuli, Shannon L. Meeks, Robert F. Sidonio, Jatin Rana, Michael U. Callaghan, Kelly Tickle, Karen L. Zimowski, Mark T. Reding

Publikováno v: Blood. 132:635-635

Introduction: Patients with severe hemophilia A and anti-factor VIII (fVIII) antibodies (inhibitors) are at risk of significant bleeding during invasive procedures. Prior to the introduction of the bispecific humanized antibody, emicizumab, the stand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd934796dbc39a35f4443c35251acf0a
https://doi.org/10.1182/blood-2018-99-115089

Zobrazit plný text záznamu

Colorectal cancer in patients 50 years and younger: The Beaumont Health System experience

Autor: John M. Robertson, Foluso Nelson Ogunleye, Daniel Isaac, Jatin Rana, Marianne Terese Huben, Ishmael Jaiyesimi, Harry Wasvary, Joseph M Anderson, Mohammed Ibrahim, Dana Zakalik, Adewale Fawole, Susanna Gaikazian

Publikováno v: Journal of Clinical Oncology. 33:e14583-e14583

e14583 Background: Colorectal cancer (CRC) is a common and lethal disease. Age is a major risk factor for developing sporadic CRC. CRC is uncommon before 50 years of age, and it is often discovered...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ccb3a45de724991219c0ba63b2416065
https://doi.org/10.1200/jco.2015.33.15_suppl.e14583

Zobrazit plný text záznamu

Heparin Induced Thrombocytopenia: Descriptive Analysis of Diagnosis and Management

Autor: Philip Kuriakose, Marilyn Karam, Jatin Rana, Mohamad A. Younes, Julio Pinto Corrales, Ahmad Mattour, Sunay Shah

Publikováno v: Blood. 118:1168-1168

Abstract 1168 Introduction: Heparin induced thrombocytopenia (HIT) is a well-recognized serious complication of heparin therapy. A key step in diagnosing HIT is the timing of ordering of the diagnostic tests, ELISA HIT antibody (HIT Ab) and the funct

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60fd9583410b151d03e62f1ad1d94e9a
https://doi.org/10.1182/blood.v118.21.1168.1168

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání